The value of ultrasound for monitoring disease activity in giant cell arteritis

Abstract

Giant cell arteritis (GCA) is the most common primary systemic vasculitis in the elderly. Although the diagnosis of GCA has improved, monitoring its disease activity remains challenging due to the lack of validated tools and biomarkers. The current reliance on assessing symptoms, physical signs, and inflammatory markers during disease follow-up presents limitations, notably the nonspecific nature of GCA-related symptoms and the suppressive impact of IL-6 inhibitors on inflammatory markers. Therefore, recent attention has shifted toward acknowledging imaging as a monitoring tool, particularly ultrasound, given its widespread accessibility, cost-effectiveness, and well-established role in GCA diagnosis. Research on this topic has found that ultrasound characteristics, including the number of affected arterial segments and halo size, are associated with laboratory markers and treatment response, underscoring the ultrasound’s potential as a monitoring tool for GCA. It has also been demonstrated that ultrasound abnormalities progress differently throughout the disease course, depending on the type of arterial involvement, with vessel wall changes in the axillary arteries resolving more slowly than those in the temporal arteries. Nevertheless, there are still no studies comparing the added value of regular ultrasounds for monitoring disease activity to clinical and laboratory monitoring alone; hence, this imaging modality is not yet recommended for patients with GCA in clinical and biochemical remission. This narrative review aims to synthesize the main research findings of key studies addressing the role of ultrasound for monitoring disease activity in GCA, with a focus on the pattern of arterial involvement. It highlights the potential of ultrasound, particularly halo sign assessment, for evaluating disease progression but notes that further validation and standardization of protocols are needed to improve accuracy and enable routine use.

Keywords

Ultrasound / monitor / giant cell arteritis / follow-up

References

[1] Jennette JC,Bacon PA.2012 Revised international chapel hill consensus conference nomenclature of vasculitides.Arthritis Rheum2013;65:1-11

[2] González-Gay MA,Llorca J.Visual manifestations of giant cell arteritis. Trends and clinical spectrum in 161 patients.Medicine (Baltimore)2000;79:283-92

[3] Dejaco C,Bond M.EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice: 2023 update.Ann Rheum Dis2024;83:741-51

[4] Ponte C,O'Neill L.Giant cell arteritis: current treatment and management.World J Clin Cases2015;3:484-94 PMCID:PMC4468893

[5] Mainbourg S,Samson M.Prevalence of giant cell arteritis relapse in patients treated with glucocorticoids: a meta‐analysis.2020;72:838-49

[6] Moreel L,Molenberghs G,Blockmans D.Epidemiology and predictors of relapse in giant cell arteritis: a systematic review and meta-analysis.Joint Bone Spine2023;90:105494

[7] Kermani TA,Cuthbertson D.Vasculitis Clinical Research ConsortiumDisease relapses among patients with giant cell arteritis: a prospective, longitudinal cohort study.J Rheumatol2015;42:1213-7

[8] Martins P,Teixeira FJ.Giant cell arteritis with normal inflammatory markers: case report and review of the literature.Clin Rheumatol2020;39:3115-25.

[9] Monti S,Luqmani RA.Systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis: focus on giant cell arteritis.RMD Open2019;5:e001003 PMCID:PMC6803016

[10] Unizony S,Miloslavsky E.Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica.Arthritis Care Res (Hoboken)2012;64:1720-9

[11] Stone JH,Dimonaco S.Glucocorticoid dosages and acute-phase reactant levels at giant cell arteritis flare in a randomized trial of tocilizumab.Arthritis Rheumatol2019;71:1329-38 PMCID:PMC6772126

[12] Tse WY,Savage CO.Assessment of disease activity in systemic vasculitis.Postgrad Med J1998;74:1-6 PMCID:PMC2360776

[13] López J, Solans Laqué R, Bosch Gil JA, Molina Cateriano C, Huguet Redecilla P, Vilardell Tarrés M. Colour-duplex ultrasonography of the temporal and ophthalmic arteries in the diagnosis and follow-up of giant cell arteritis.Clin Exp Rheumatol2009;27:S77-82

[14] Evangelatos G,Iliopoulos A.Temporal ultrasound for monitoring tocilizumab treatment in giant cell arteritis: seeing beyond serum markers?.Ann Rheum Dis2021;80:e184

[15] Ford JA,Huang W,Docken WP.Follow-up vascular ultrasounds in patients with giant cell arteritis.Clin Exp Rheumatol2020;38:107-11 PMCID:PMC7812681

[16] Habib HM,Hassan AA.Color duplex ultrasonography of temporal arteries: role in diagnosis and follow-up of suspected cases of temporal arteritis.Clin Rheumatol2012;31:231-7

[17] Aschwanden M,Imfeld S.Vessel wall plasticity in large vessel giant cell arteritis: an ultrasound follow-up study.Rheumatology (Oxford)2019;58:792-7

[18] Bosch P,Schmidt WA,Pregartner G.Ultrasound for diagnosis and follow-up of chronic axillary vasculitis in patients with long-standing giant cell arteritis.Ther Adv Musculoskelet Dis2021;13:1759720X21998505 PMCID:PMC7983430

[19] Ponte C,Scirè CA.Ultrasound halo sign as a potential monitoring tool for patients with giant cell arteritis: a prospective analysis.Ann Rheum Dis2021;80:1475-82

[20] Ponte C,Monti S.Early variation of ultrasound halo sign with treatment and relation with clinical features in patients with giant cell arteritis.Rheumatology2020;59:3717-26

[21] Monti S,Ponte CB.The proposed role of ultrasound in the management of giant cell arteritis in routine clinical practice.Rheumatology (Oxford)2018;57:112-9

[22] Czihal M,Schroettle A,Schulze-Koops H.Outcome of giant cell arteritis of the arm arteries managed with medical treatment alone: cross-sectional follow-up study.Rheumatology (Oxford)2013;52:282-6.

[23] Seitz L,Lötscher F.Quantitative ultrasound to monitor the vascular response to tocilizumab in giant cell arteritis.Rheumatology (Oxford)2021;60:5052-9 PMCID:PMC8566271

[24] Nielsen BD,Keller KK,Hansen IT.Ultrasonography in the assessment of disease activity in cranial and large-vessel giant cell arteritis: a prospective follow-up study.Rheumatology (Oxford)2023;62:3084-94

[25] Miguel E, Roxo A, Castillo C, Peiteado D, Villalba A, Martín-Mola E. The utility and sensitivity of colour Doppler ultrasound in monitoring changes in giant cell arteritis.Clin Exp Rheumatol2012;30:S34-38

[26] Chrysidis S,Dejaco C.Definitions and reliability assessment of elementary ultrasound lesions in giant cell arteritis: a study from the OMERACT Large Vessel Vasculitis Ultrasound Working Group.RMD Open2018;4:e000598 PMCID:PMC5976098

[27] Salvarani C,Ghirarduzzi A.Is duplex ultrasonography useful for the diagnosis of giant-cell arteritis?.Ann Intern Med2002;137:232-8

[28] Czihal M,Baustel K,Dechant C.B-mode sonography wall thickness assessment of the temporal and axillary arteries for the diagnosis of giant cell arteritis: a cohort study.Clin Exp Rheumatol2017;103:128-33

[29] Karahaliou M,Papaspyrou S,Revenas K.Colour duplex sonography of temporal arteries before decision for biopsy: a prospective study in 55 patients with suspected giant cell arteritis.Arthritis Res Ther2006;8:R116 PMCID:PMC1779378

[30] Schäfer VS,Ramiro S,Schmidt WA.Ultrasound cut-off values for intima-media thickness of temporal, facial and axillary arteries in giant cell arteritis.Rheumatology2017;56:1479-83

[31] Ghinoi A,Nicolini A.Large-vessel involvement in recent-onset giant cell arteritis: a case-control colour-Doppler sonography study.Rheumatology (Oxford)2012;51:730-4

[32] Förster ,Weiss .Patterns of extracranial involvement in newly diagnosed giant cell arteritis assessed by physical examination, colour coded duplex sonography and FDG-PET.Vasa2011;40:219-27

[33] Hauenstein C,Geiger J.Effects of early corticosteroid treatment on magnetic resonance imaging and ultrasonography findings in giant cell arteritis.Rheumatology (Oxford)2012;51:1999-2003

[34] Schmidt WA,Seifert A,Gromnica-ihle E.Prognosis of large-vessel giant cell arteritis.Rheumatology2008;47:1406-8

[35] Aschwanden M,Stern M.Vascular involvement in patients with giant cell arteritis determined by duplex sonography of 2x11 arterial regions.Annals of the Rheumatic Diseases2010;69:1356-9

[36] Sebastian A,Prieto-pena D.Efficacy and safety of tocilizumab in giant cell arteritis: a single centre NHS experience using imaging (ultrasound and PET-CT) as a diagnostic and monitoring tool.RMD Open2020;6:e001417 PMCID:PMC7856116

[37] Luqmani R,Singh S.The role of ultrasound compared to biopsy of temporal arteries in the diagnosis and treatment of giant cell arteritis (TABUL): a diagnostic accuracy and cost-effectiveness study.Health Technol Assess2016;20:1-238 PMCID:PMC5165283

[38] Dejaco C,Monti S.The provisional OMERACT ultrasonography score for giant cell arteritis.Ann Rheum Dis2023;82:556-64